← FDA DRUG APPROVALS

FDA NDA · NDA209229

LUCEMYRA

lofexidine hydrochloride

Sponsor: BIOCORRX PHARMS

APPLICATION
NDA209229
TYPE
NDA
ORIGINAL APPROVAL
2018-05-16
LATEST ACTION
2024-09-05
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

LUCEMYRA · ReferencePrescription
LOFEXIDINE HYDROCHLORIDE EQ 0.18MG BASE · TABLET · ORAL

Approval history

2024-09-05Labeling · Supplement 7 · standard — Label ↗AP
2018-05-16Type 1 - New Molecular Entity · Original · priority — Label ↗AP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →